CACNA1C polymorphisms are associated with the efficacy of calcium channel blockers in the treatment of hypertension
CACNA1C polymorphisms are associated with the efficacy of calcium channel blockers in the treatment of hypertension
复制标题
DOI：
10.2217/14622416.7.3.271
复制
发表时间：
2006-04-01
期刊：
影响因子：
2.1
通讯作者：
Diamond, C
中科院分区：
文献类型：
--
作者：
Bremer, T;Man, A;Diamond, C
对120例白人受试者进行了回顾性药物遗传学分析。受试者是与爱沙尼亚基因组计划和Egeen Inc.合作获得的。(CA，美国），他们分别向研究人员提供了盲态医疗记录和遗传数据。从爱沙尼亚基因组计划中选择的受试者诊断为高血压，经至少两次血压测量和多次随访测量证实，用于评估钙通道阻滞剂抗高血压治疗结局。如果至少3次随访血压测量结果为非高血压，且不超过1次随访血压测量结果为高血压（>140/90），则治疗结局评分为阳性。从每个受试者的血液样本中获得钙通道电压依赖性L型α 1C亚基（CACNA 1C）基因的62个单核苷酸多态性（SNP）的基因型。使用家族错误率和错误发现率方法进行了具有多重检验校正的单变量分析。CANCA 1C中的三个SNP与抗高血压结局显著相关，结合产生小于15%至80%的积极治疗结局。
Retrospective pharmacogenetic analysis was performed on 120 Caucasian subjects. Subjects were obtained in collaboration with the Estonian Genome Project and Egeen Inc. (CA, USA), who provided blinded medical record and genetic data to the researchers, respectively. Subjects selected from the Estonian Genome Project had a diagnosis of hypertension confirmed by at least two blood pressure measurements and multiple follow-up measurements for assessing calcium channel blocker antihypertensive treatment outcome. Treatment outcome was scored positive if at least three follow-up blood pressure measurements were nonhypertensive and no more than one follow-up measurement was hypertensive (>140/90). The genotypes of 62 single nucleotide polymorphisms (SNPs) in the calcium channel, voltage-dependent, L type, alpha 1C subunit (CACNA1C) gene were obtained for each subject from a blood sample. Univariate analyses with multiple test correction were conducted using family-wise error rate and false discovery rate methods. Three SNPs in CANCA1C had significant associations with anti hypertensive outcome, combining to yield a positive treatment outcome of less than 15 to 80%.